ADA in Immuno-oncology: Opportunities and Challenges

Drug-induced immunogenicity is a significant challenge for biological drugs. Biological drugs such as antibodies, proteins, and peptides are large and complex structures. These complex drug products induce innate immune responses in patients leading to anti-drug antibodies (ADA) formation. ADA can inactivate the pharmaceutical drug,  affect its targeting ability, and increase the clearance of ADA drug […]

Continue Reading